テノホビル、エムトリシタビン（またはラミブジン）＋ロピナビルの継続投与と、ラルテグラビル＋ダルナビルへの切り替えの比較

基本情報

NCT ID

NCT01294761

ステータス

完了

試験のフェーズ

該当なし

試験タイプ

介入

目標被験者数

59

治験依頼者名

National Center for Global Health and Medicine, Japan

概要

The main objective of this clinical trial in randomizing HIV infected patients under good HIV control with tenofovir (TDF), emtricitabine (or lamivudine) plus lopinavir/ritonavir (LPV/r) into switching the regimen to raltegravir (RAL) with darunavir/ritonavir (DRV/r) or continuing the ongoing regimen to compare these two groups' estimated glomerular filtration rate (eGFR) is to investigate whether anti-HIV treatment that does not contain TDF or other reverse-transcriptase inhibitors (NTRI sparing regimen) can be protective of patients' renal functions and has the same virological efficacy in comparison with a standard treatment with TDF, or not.

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)